Levoxacin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levoxacin

Levoxacin is a powerful synthetic antibiotic prescribed to fight a wide range of bacterial infections throughout the body. The medication is considered a single-component product whose active substance is Levofloxacin (INN).

Property Description
Active ingredient Levofloxacin
Form Tablet, solution for infusion, ophthalmic/otic solutions
Pharmacological class Third-Generation Fluoroquinolone Antibiotic
Common use Resolution of bacterial infections
Origin Synthetic

Levofloxacin: Identity, Origin, and Active Ingredient

Levofloxacin is the active component that gives Levoxacin its therapeutic action. The substance itself is a purified S-isomer of the older drug Ofloxacin, chemically produced through synthesis, making it a synthetic compound rather than one derived from natural organisms. The purification to the S-enantiomer is clinically recognized for providing a more potent and focused activity profile compared to the original Ofloxacin compound. This single-component structure ensures a reliable, focused antimicrobial effect, making it a key element in managing infectious disease.

What Pharmacological Class Does Levofloxacin Belong To?

Levofloxacin belongs to the quinolone antibiotic class, specifically designated as a third-generation fluoroquinolone. This classification identifies the drug as a powerful broad-spectrum agent that can target a wide variety of bacterial pathogens. Scientific consensus, supported by numerous pharmacological studies, confirms Levofloxacin's utility against both Gram-negative and Gram-positive organisms. To address infections in different body systems, the medicine is supplied in various dosage forms, including the tablet for oral intake, a solution for infusion for intravenous delivery, and specialized ophthalmic and otic solutions for topical administration.

The General Purpose of Levofloxacin: Bactericidal Action

The general purpose of Levofloxacin is to resolve bacterial infections by killing the pathogenic organisms outright. It achieves this by exerting a bactericidal action—a direct killing effect—which is the functional principle that sets it apart from antibiotics that merely inhibit bacterial growth. This powerful mechanism helps to eliminate the infectious source and is the key functional principle behind the drug's overall utility in managing systemic and localized bacterial threats. This ability to destroy bacteria is essential for the rapid clearance of infectious sources in scenarios such as typical community-acquired infections.

Regulatory References

  1. NIH: Levofloxacin - StatPearls
  2. MedlinePlus: Levofloxacin - NIH

What side effects are possible with Levoxacin?

Possible side effects and safety information

Levoxacin (Levofloxacin) has an officially documented safety profile, with potential adverse reactions systematically classified by frequency and affected body system in regulatory labels.


Frequency-Classified Adverse Reactions

The frequency of reported adverse reactions is categorized in official documents, with the most common being gastrointestinal and neurological:

Classification Representative Adverse Reactions
Common (ge1%) Nausea, Diarrhea, Headache, Insomnia, Dizziness
Uncommon (ge0.1% to <1%) Anxiety, Confusion, Tremor, Rash, Vomiting, Constipation
Rare (ge0.01% to <0.1%) Tendinitis, Paresthesia, Psychotic Reactions, Convulsions

Serious Adverse Reactions and Safety Constraints

Regulatory authorities document specific serious adverse reactions that can be disabling and potentially irreversible, often affecting multiple systems. These include Tendinitis and Tendon Rupture, Peripheral Neuropathy, and certain Central Nervous System effects (e.g., seizures, severe psychiatric reactions).

Other serious considerations involve cardiac function (QT interval prolongation), liver damage (severe hepatotoxicity), and the risk of Aortic Aneurysm and Dissection. These serious effects may occur early in treatment or months after discontinuation.

Safety notes specify heightened risk in older adults (aged ge60 years) and in patients receiving corticosteroids, due to increased susceptibility to tendon disorders. Use is also constrained in patients with a history of Myasthenia Gravis.

Overdose and Emergency Response

Overdose with Levofloxacin is associated with specific clinical manifestations officially documented in government regulatory labels. These presentations primarily involve the Central Nervous System (CNS), characterized by signs such as tremors, confusion, dizziness, and somnolence (drowsiness). A severe escalation of CNS toxicity may include documented instances of convulsions (seizures). Furthermore, excessive exposure affects the Cardiovascular System, with official documents citing prolongation of the QT interval on an electrocardiogram (ECG), which carries the risk of life-threatening arrhythmias.

In all cases of suspected overdose, official regulatory guidance mandates that individuals must seek emergency medical attention immediately. The medication must be discontinued at the first sign of serious adverse events. Management relies entirely on symptomatic and supportive treatment, as no specific antidote is known. Close ECG monitoring is required due to the cardiac risks.

Overdose risk is considered elevated in patients with renal impairment because the drug is primarily cleared by the kidneys, and specific regulatory warnings exist for older patients and diabetics regarding severe outcomes like hypoglycaemic coma.

Therapeutic Uses of Levoxacin

Levofloxacin is a systemic fluoroquinolone antibiotic commonly used in managing infections caused by susceptible bacteria. It is applied across domains where additional symptomatic support is needed, and is considered relevant in clinical settings that involve acute or unstable symptom patterns. The drug is primarily used in conditions characterized by periods of heightened symptoms in the respiratory tract, the skin and skin structure, and the urinary tract and kidneys.

This medication helps address symptom clusters that may become intense or disruptive in common clinical scenarios such as community-acquired pneumonia, acute bacterial sinusitis, skin infections, complicated urinary tract infections, and pyelonephritis. Its application provides support that helps ease the overall symptom burden.

“It provides supportive relief when symptoms interfere with routine activities.”

Quick Fact: Supportive management for Symptoms related to physical discomfort

Eligibility and Restrictions for Use

Official Population Eligibility for Levofloxacin

Levofloxacin eligibility is defined by regulatory bodies to ensure appropriate use and manage specific population risks. The medicine is primarily indicated for use in adults (generally 18 years and older).

Absolute Contraindications

Population Group Restriction Type
Pregnancy and Breast-feeding Contraindicated
History of Epilepsy Contraindicated
Hypersensitivity to quinolones Contraindicated
History of fluoroquinolone-related tendon disorders Contraindicated

Restricted or Conditional Use

Population Group Required Condition
Children and Growing Adolescents Contraindicated, except for specific, designated life-threatening infections (e.g., anthrax) [FDA].
Renal Impairment Mandatory dose adjustment is required when creatinine clearance is le 50 mL/min, as the drug is primarily eliminated by the kidneys.
Concomitant Corticosteroid Use Use must be avoided due to a significantly increased risk of tendon rupture.
Myasthenia Gravis Use should be avoided (risk of exacerbation).

Eligibility in older adults may require caution and kidney function assessment. This information reflects official, label-based regulatory guidelines.

What should I know about interactions with other medicines?

Documented Interaction Profile

The official regulatory profile for Levoxacin (Levofloxacin) interactions is established through documented patterns of pharmacokinetic and pharmacodynamic effect modification with various substances.

Interaction Classifications

Classification Type Examples of Interacting Agent Classes
Exposure-Modifying Multivalent cation-containing products, Probenecid, Cimetidine
Pharmacodynamic Risk QT-prolonging drugs, Warfarin, Antidiabetic agents, Corticosteroids

Official Interaction Statements

  • Chelation and Absorption: The co-administration of oral Levofloxacin with multivalent cation-containing products (such as antacids, iron salts, or Sucralfate) is documented to decrease its absorption.
  • Timing Separation: To counter this effect, the tablet or oral solution formulation must not be taken within 2 hours of these cation-containing products, as officially specified.
  • Clearance Alteration: Co-administration with Probenecid and Cimetidine is noted in regulatory sources to reduce Levofloxacin renal clearance, resulting in higher systemic exposure.
  • Contraindicated Risk: Combining Levofloxacin with medicines that prolong the QT interval (e.g., Class IA and III antiarrhythmics, macrolides, antipsychotics) is restricted due to the official risk of additive cardiotoxicity.
  • Population Note: The interaction with Corticosteroids carries an increased risk of tendinopathy, which is officially documented as further heightened in elderly patients.
  • Food Intake: The official labeling states there is no clinically relevant interaction between the oral tablet formulation and food.

This structured regulatory profile provides a framework for understanding required restrictions, timing separation rules, and specific cautions based strictly on government-approved drug label information.

Mechanism of Action

How Levoxacin Works

Disrupting Essential Bacterial DNA Maintenance

Levoxacin operates by directly inhibiting two critical bacterial enzymes: DNA gyrase and topoisomerase IV. This action prevents the enzymes from correctly unwinding, copying, and resealing the bacterial cell's genetic material (DNA), thereby blocking the entire process of genetic maintenance. This mechanism is characteristic of quinolone drugs, which focus on direct intracellular damage via DNA replication interference, rather than mechanisms driven primarily by cell wall synthesis or protein production.


Inducing Irreversible Cellular Damage

The interference with these essential enzymes initiates a mechanistic cascade resulting in widespread, irreversible double-strand breaks in the bacterial DNA. This extensive genetic damage leads to the subsequent cessation of bacterial growth and the eventual death of the target bacterial cell. This cellular event is a critical physiological consequence of the drug's action, resulting in the reduction of bacterial viability within the affected system.

Dosage and Administration Information

Levoxacin is administered for systemic use via the oral route (tablets or solution) and the intravenous (IV) infusion route, a flexibility which supports sequential therapy—a switch from IV to oral administration at the equivalent dose to complete the course. The dosage for adults is prescribed once daily, with the standard range varying from 250 mg to 750 mg, a choice determined by the specific infection being managed. The total duration of use is also indication-dependent, lasting from 3 days for short courses up to 60 days for certain prophylactic regimens.

Proper administration involves specific timing constraints. While oral tablets can be taken without regard to meals, all oral forms must be administered at least 2 hours before or 2 hours after consuming products containing multivalent cations, such as iron, zinc, or magnesium/aluminum antacids, to prevent poor absorption. For patients requiring IV delivery, the medication must be given only as a slow intravenous infusion, lasting a minimum of 60 minutes for 250 mg or 500 mg doses, and at least 90 minutes for the 750 mg dose.

A critical procedural rule is the need for dose modification in specific populations. An adjustment to the standard dose or dosing interval is required for patients with renal impairment (reduced kidney function) to avoid drug accumulation; however, no dose adjustment is necessary for hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Levoxacin

Evidence for Use in Respiratory Tract Infections

The body of research supporting these uses includes large-scale Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. Levoxacin (Levofloxacin) was studied for use in systemic bacterial infections within the respiratory system, such as Community-Acquired Pneumonia (CAP) and Nosocomial Pneumonia (hospital-acquired). Researchers monitored several key outcomes, including clinical response rates (describing changes in symptoms over the study period), microbiological eradication, and overall patterns related to survival in the adult study populations.

Despite the extensive research, certain aspects remain uncertain. Long-term effects are not fully established, and studies report that outcomes observed are closely associated with the rising resistance of common respiratory pathogens. For less severe infections like acute bacterial sinusitis, research is limited compared to other widely available treatments, and long-term outcomes are not the primary focus.


Evidence for Use in Urinary Tract and Kidney Infections

The research was evaluated in studies for conditions like Complicated Urinary Tract Infections (cUTI) and Acute Pyelonephritis (a kidney infection). This research is built upon numerous Phase 3 Randomized Controlled Trials that examined outcomes related to systemic or functional imbalance.

The studies focused on two main outcome areas: clinical response rates (reporting on changes in patient-reported outcomes describing perceived discomfort) and microbiological eradication. Data show patterns related to outcomes observed being closely associated with the sensitivity of the isolated bacteria, and there is limited information on the effects of increasing antibiotic resistance among common urinary tract pathogens.


Research for Specialized and Preventive Applications

The research for specialized and preventive applications differs significantly. For the prevention of active tuberculosis (TB) in contacts of drug-resistant cases, the research was evaluated through Randomized, Placebo-Controlled Trials, monitoring the incidence of active TB disease over many months.

For managing Inhalational Anthrax or Plague post-exposure, evidence is not based on direct human trials. Instead, it relies on Animal Efficacy Studies and Human Pharmacokinetic (PK) Studies. The achievement of required drug levels in the blood was associated with the outcome assessed in animal models. Certainty remains low because efficacy is an inference and not based on direct human patient outcomes.

Key Studies & References

  1. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Levoxacin (FAQ)

Q: What happens if I forget to take a dose of Levoxacin?

Official administration instructions describe the procedure for a missed dose. If a dose is forgotten, official guidance indicates that it may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the official guidance is to skip the missed dose entirely. A double dose is generally advised against.


Q: Does Levoxacin interact with any common over-the-counter pain relievers?

Regulatory documents indicate a potential interaction between Levoxacin and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes many common pain relievers. This combination carries a described risk of increasing central nervous system effects. This potential interaction is discussed in official labeling.


Q: Are there any specific Black Box Warnings for Levoxacin in the United States?

Yes, official U.S. regulatory labeling for fluoroquinolones like Levoxacin includes a Boxed Warning regarding serious adverse reactions. This warning describes the risk of disabling and potentially irreversible effects, such as damage to tendons (tendinitis/tendon rupture), nerve damage (peripheral neuropathy), and central nervous system issues. This is an important safety classification defined by the FDA.


Q: How long does Levoxacin stay active in the body after the last dose?

Scientific data on the active ingredient, Levofloxacin, describes its rate of elimination from the body using a measure called the half-life. This half-life typically ranges from 6 to 12 hours in patients with normal kidney function. This information indicates how long the medication's concentration takes to decrease by half, providing an estimate of how long the substance remains in the system.


Q: Does taking Levoxacin affect your sensitivity to the sun?

Official safety information classifies Levoxacin as a photosensitizing agent. This means that taking the drug may significantly increase the skin's sensitivity to sunlight or UV light. Regulatory information notes that exposure, even for brief periods, may cause severe sunburn or a rash, and notes the importance of minimizing unnecessary sun exposure.


Q: What are the signs of a severe allergic reaction to Levoxacin?

Regulatory documents list several signs associated with severe reactions that may necessitate a review of treatment. These symptoms may include hives, swelling of the lips, tongue, or face, throat tightness, hoarseness, and difficulty breathing or swallowing. A rapid or pounding heartbeat and fainting are also described as potential signs.


Q: Does Levoxacin interact with birth control medication?

Information suggests that Levoxacin may interact with certain hormone-based birth control medications. Regulatory warnings indicate that the medication may reduce the effectiveness of birth control pills that contain hormones like ethinyl estradiol. This potential interaction may increase the risk of pregnancy.


Q: What should I do if I accidentally take more Levoxacin than prescribed?

The overdosage section in official labeling states that in the event of accidentally taking too much Levoxacin, medical observation is often necessary. It is also noted that appropriate hydration should be maintained. Regulatory documents confirm that the active substance is not efficiently removed by standard hemodialysis procedures.


Q: Does Levoxacin cause temporary or permanent changes in vision?

Changes in vision, including blurred vision, have been reported as possible adverse reactions in the post-marketing safety experience for Levofloxacin. This information is noted in regulatory documents as a potential effect.


Q: Can Levoxacin be used in older adults?

Official documentation indicates there is no specific upper age restriction for the use of Levoxacin. However, safety notes specify that older adults, generally those aged 60 years and above, have a heightened risk for certain serious adverse reactions, such as tendon disorders. Official documentation notes that caution and assessment of kidney function may be considered for this population.


Q: Are there any foods or drinks that should be strictly avoided with Levoxacin?

Official labeling states that the Levoxacin oral tablet can be taken without concern for general meals or food intake. However, the medication is recommended to be separated by at least two hours from consuming products that contain multivalent cations. This includes supplements containing minerals like iron or zinc, as well as magnesium/aluminum antacids, because these can reduce the drug's absorption.


Q: Can people with pre-existing heart conditions take Levoxacin?

Regulatory warnings advise caution due to Levoxacin's association with QT interval prolongation, which is a change in the heart's electrical activity. Official regulatory warnings describe restrictions on use for patients with a known history of this condition, very low potassium levels (hypokalemia), or those taking certain other medicines known to affect the QT interval.


Q: Can Levoxacin affect blood sugar levels in people with diabetes?

Official documents confirm that Levoxacin may cause disturbances in blood sugar regulation, specifically reporting both increases (hyperglycemia) and decreases (hypoglycemia) in glucose levels. Due to this potential effect, the medication is noted to interact with antidiabetic agents or insulin.


Q: Can Levoxacin be taken with milk or dairy products?

The official guidance relates to products that contain multivalent cations, which includes the calcium found in milk and fortified dairy products. To help prevent potential poor absorption, separation by at least two hours is generally described in administration guidance, consistent with the rule for mineral supplements and antacids.


Q: What is the official recommended age limit for using Levoxacin?

Regulatory sources generally indicate Levoxacin is for use in adults (typically 18 years and older). Use in children and growing adolescents is considered restricted except for very limited, specific life-threatening infections, such as anthrax, where it may be permitted for patients as young as 6 months.


Q: Are there any known long-term effects associated with Levoxacin?

Official regulatory warnings describe the risk of certain serious adverse reactions, such as nerve damage (peripheral neuropathy) and tendon rupture, as being long-lasting or potentially irreversible. These effects are officially noted to sometimes manifest or be recognized months after treatment with the medication has been completed.


Q: Is it possible to develop a resistance to Levoxacin?

Scientific and regulatory information indicates that it is possible for bacteria to develop resistance to the active ingredient in Levoxacin. This process may involve bacteria undergoing genetic changes that modify the targets of the drug, thus reducing the medication's ability to kill the pathogens.

How should Levoxacin be stored and disposed of?

How to Store and Dispose of Levoxacin?

This section outlines the official, label-based requirements for storing and discarding the medicine, as defined by regulatory agencies.

Product Form Temperature & Protection Specific Requirements
Tablets Store at controlled room temperature (15 C to 30 C / 59 F to 86 F). Store in well-closed containers.
Injection Solution Store at 20 C to 25 C (68 F to 77 F); refrigeration (2 C to 8 C) is also permitted. Must be protected from light and supplied as single-use.

All forms of Levoxacin must be protected from freezing and from excessive heat, as specified in the official labeling. The medicine must be kept out of reach of children. Any unused, expired, or leftover solution from the single-use container must be discarded properly and in compliance with all relevant local, regional, and national regulations; disposal into drains or waterways must be avoided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levoxacin found in:

A-Z Index: